tbuckley/cabot-search huggingface dataset:
The Role of Rifampin in Leprosy
Authors: Herbert B. Allen, Samuel L. Moschella
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Thrombopoietin Regulates Proliferation and Maturation of Murine Mast Cells.
Authors: Giovanni Migliaccio, Barbara Ghinassi, Lucia Centurione, Maria Zingariello, Lucia Bianchi, Alessandro Pancrazi, Francesco Paoletti, Alessandro M. Vannucchi, Rosa Alba Rana, Mitsuo Nishikawa, Anna Rita Migliaccio
Journal: Blood (2004)
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
Authors: Ghassan K. Abou-Alfa, Chia-Jui Yen, Jorge A. Carrasquillo, Chih-Hung Hsu, Bolorsukh Gansukh, Jennifer Ma, Ellen Hollywood, Peter J Wan, Yu Yun Shao, Zhong-Zhe Lin, Catherine Frenette, Bert H. O'Neil, Lawrence H. Schwartz, Toshihiko Ohtomo, Takayoshi Tanaka, Ya-Chi Chen, Stacey Ukrainskyj, Leonard Saltz, Reuy-min Lee, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2014)

4100 Background: GC33 is a recombinant humanized monoclonal antibody against Glypican-3 (GPC3) which is highly expressed in HCC. GC33 elicits antibody-dependent cellular cytotoxicity against human HCC cell lines in vitro. GC33 and sorafenib showed an additive anti-tumor effect in xenograft mouse model. This is a phase I dose escalation study to evaluate safety/tolerability and pharmacokinetics (PK) of combination therapy in HCC. Methods: In a 3+3 design dose escalation design GC33 given intravenously 2.5, 5 and 10 mg/kg weekly, then 1,600 mg every 2 weeks, and then 1,600mg weekly, all in combination with sorafenib 400mg twice daily. Patients with advanced HCC patients, age ≥18, ECOG 0-1, Child-Pugh A, adequate organ functions (platelets ≥ 100 x109/L, ANC ≥ 1500, AST/ALT ≤ 5 x ULN, Bilirubin ≤ 1.5 mg/dL, and creatinine ≤ 2 x ULN), and no prior therapy with sorafenib were eligible. Primary endpoints were safety and tolerability and secondary endpoints PK of GC33 and sorafenib and efficacy. Tumor assessment was based on investigators using RECIST 1.0. Safety was evaluated by CTCAE 3.0. Results: 40 patients were enrolled between September 2009 and July 2013 as follows (n): 2.5 mg/kg weekly (qw) (12), 5 mg/kg qw(12), 10 mg/kg qw(3), 1,600mg q2w (6) and 1,600mg qw (7). There were 35 men/5 women, median age 60, Asian 21/Non-Asian 19, HBV /HCV/neither 19/9/13, ECOG 0/1 17/23. There were 3 DLT: Grade 3 hyponatremia at 5 mg/kg GC33 cohort, grade 3 hyponatremia and hypoglycemia at 1600mg q2w, and grade 3 ALT increase at 1600 mg qw. Thirty-six patients developed AE’s ≥ Grade 3, including 10 (25%) with increased Lipase, 10 (25%) with increased AST, and 3 (7.5%) with increased ALT. Dose delays occurred in 6/7 patients receiving GC33 1600mg qw due to known sorafenib-related toxicities. There were no complete responses, one partial response (unconfirmed), and 6 patients (15%) have experienced stable disease for ≥ 5 months. PK parameters Cmax and AUCt of GC33 and sorafenib following combination therapy were comparable to previously reported data of either single agent. Conclusions: No maximum tolerated dose of GC33 could be defined when given in combination with sorafenib at the dose of 400mg bid in this study population. Clinical trial information: NCT00976170.
Biweekly irinotecan in combination with gemcitabine (G), 5-Fluorouracil (5-FU), leucovorin (LV) and cisplatin (G-FLIP) associated with encouraging activity in patients with metastatic pancreatic cancer: Update of a phase I-II trial
Authors: R. Rachamalla, S. Malamud, M. L. Grossbard, S. Mathew, M. Dietrich, P. S. Kozuch
Journal: Journal of Clinical Oncology (2004)

4189 Background: This phase I-II study of irinotecan in combination with fixed doses of gemcitabine, 5-FU/LV and cisplatin was initiated based on encouraging clinical data with G-FLIP in the therapy of solid tumors. In this trial, G-FLIP has been modified to facilitate outpatient administration and to optimize sequence dependent synergistic activity. Patients and Methods: Phase II therapy consisted of biweekly cycles of sequential gemcitabine 500mg/m2, irinotecan 120 mg/m2, bolus 5-FU 400mg/m2 and LV 300mg on Day 1 followed by a 24 hour 5-FU infusion 1500mg/m2, followed by cisplatin 35 mg/m2 on Day 2. These doses were based on published phase I data. Eighteen patients (pts.) with biopsy confirmed metastatic pancreatic adenocarcinoma have been enrolled to date and sixteen are evaluable for response. Median pt. age was 57 years (range 41–78) and median Karnofsky performance status (KPS) was 85. Results: Pts. have received a median of 8.5 cycles (range 1–16). Sixteen pts. are eligible for evaluation following a minimum of 4 cycles of GFLIP. Per RECIST criteria, 3 pts. (19%) have attained a partial response and 7 (43%) attained disease stabilization. Grade 3–4 toxicities per pt. have largely been hematological and consisted of neutropenia (19%) with neutropenic fever observed in 13%. Time to disease progression (TTP) ranges from 3 weeks (early progression) to 47 weeks, median TTP will be more than 11 weeks. Median survival will be more than 12 weeks and ranges from 3 to 79 weeks. Conclusion: G-FLIP is a novel outpatient chemotherapy regimen with acceptable toxicity and encouraging activity in patients with metastatic pancreatic cancer. Patient accrual and follow-up is ongoing and updated outcomes will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Lilly; Pfizer Pfizer
Cerebrospinal Fluid Immunophenotyping in B-Cell Lymphomas: A Single Centre Experience on 99 Samples.
Authors: Anne Plonquet, Jehan Dupuis, Christo Christov, Christiane Copie-Bergman, Karim Belhadj, Taoufik El Gnaoui, Isabelle Gaillard, Corinne Haioun
Journal: Blood (2007)
Adenovirus and BK Virus Co-Infection in the Pediatric Recipient of Stem Cell Transplant with CMV Infection.
Authors: Suradej Hongeng, Siriorn Watcharananan, Usanarat Anurathapan, Wisutwadee Piyatuctsanawong, Samart Pakakasama, Nongnuch Sirachainan, Sayomporn Sirinavin, Wasan Chantratita
Journal: Blood (2007)
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma
Authors: Matteo Manfredi, Mario Airoldi, Marcello Tucci, Consuelo Buttigliero, Antonella Parente, Tiziana Angusti
Journal: Clinical Nuclear Medicine (2017)

Salivary duct carcinoma (SDC) is a rare malignancy, frequently overexpressing androgen receptor (AR). Therefore, similar to AR-positive prostate cancer (PCa), AR-positive SDC patients benefit from androgen deprivation therapy and, after progression on ADT, might take advantage of Ra dichloride, a radiopharmaceutical approved for the treatment of castration-resistant PCa with symptomatic bone disease. We report the case of a 75-year-old man with castration-resistant SDC and osteoblastic bone metastases who, after Ra treatment, achieved adequate control of bone pain and bone lesion reduction with minor side effects. Evaluation of this strategy in other patients with similar characteristics is warranted.
Bioimpedance spectroscopy for lymphedema assessment: Clinical practice guidelines.
Authors: Chirag Shah, Frank A. Vicini, Douglas W. Arthur
Journal: Journal of Clinical Oncology (2016)

146 Background: Breast cancer related lymphedema (BCRL) is an increasingly diagnosed complication of breast cancer treatment with incidence rates of 5% with lumpectomy alone to more than 40% with mastectomy, axillary dissection, and radiation therapy. Increasing data supports the role of early detection and treatment with one diagnostic modality being bioimpedance spectroscopy (BIS) with L-Dex measurements. Methods: A systematic review of the National Library of Medicine’s PubMed search was performed for articles applicable to BIS and BCRL. Clinical guidelines were created by the authors based on published data and consensus agreement. Results: At this time, multiple randomized and prospective trials have been performed evaluating early detection for BCRL and have demonstrated reduced rates of BCRL with such an approach. BIS with L-Dex represents a technique with published literature supporting increased sensitivity, ability to detect subclinical BCRL and standardized clinical decision points, an improvement from traditional BCRL diagnostics. BCRL surveillance programs should focus on high-risk patients including those undergoing mastectomy, axillary lymph node dissection, sentinel node biopsy with greater than 6 nodes sampled, regional nodal irradiation, and those requiring taxane based chemotherapy. Patients should undergo assessment prior to locoregional therapy and then every 3 months for the first 3 years with additional measurements made based on clinical assessment. A change in L-Dex of 10 has been utilized has a consistent trigger to initiate BCRL treatment. Conclusions: With increasing data supporting early diagnosis and treatment of BCRL, these guidelines offer clinicians a tool to help develop BCRL surveillance programs as part of routine breast cancer care.
Pyrimethamine Does Not Diminish Lymphoproliferation in MRL/lpr−/− Mice and Patients with Autoimmune Lymphoproliferative Syndrome (ALPS).
Authors: V. Koneti Rao, Kennichi C. Dowdell, Faith Dugan, Janet K. Dale, Lesley Pesnicak, Lilia Bi, Scott Penzak, Nilo A. Avila, Thomas A. Fleisher, Jennifer M. Puck, Stephen E. Straus
Journal: Blood (2005)
An interim assessment of key biomarkers (programmed cell death receptor ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) in third-line therapy non-small cell lung cancer (NSCLC) patients: A Danish cohort study
Authors: D. Cronin-Fenton, T. Dalvi, E. Hedgeman, M. Norgaard, L. Pedersen, K. Mortensen, A. Midta, N. Shire, R. Brody, J. Fryzek, D. Lawrence, J. Rigas, D. Potter, J. Walker, A. Mellemgaard, T.R. Rasmussen, S. Hamilton-Dutoit, H.T. Sørensen
Journal: Annals of Oncology (2016)
Response to: ‘Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis’ by Raychaudhuri<i>et al</i>
Authors: Trudy McGarry, Wei Gao, Douglas J Veale, Ursula Fearon
Journal: Annals of the Rheumatic Diseases (2017)

In their correspondence, Raychaudhuri et al 1 describe an alternative mechanism for the role of Janus Kinase and Signal Transducer and Activator of Transcription (JAK/STAT) signalling in the pathogenesis of psoriatic arthritis (PsA). The interleukin (IL)-23/IL-17 cytokine axis is a well-documented and prominent pathway in the understanding of the pathogenesis of PsA, indicated by the approval of the monoclonal antibody (mAb) ustekinumab, a fully human Ig G1k mAb against the common subunit p40 of IL-12 and IL-23, for the treatment of psoriasis and PsA by the European Medicines Agency and Food and Drug Administration.2 In addition, IL-17 itself is also a direct therapeutic target for the treatment of PsA and psoriasis, with IL-17A mAb secukinumab now approved also for PsA and psoriasis.3 ,4 We agree that the tofacitinib may function by inhibiting JAK2/STAT3, leading to an inhibition of the functional effects of IL-23 on memory T cells, with an ultimate consequence …
186P Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable liver-only metastatic colorectal cancer: A multi-center, single-arm phase II study
Authors: D.-S. Wan, S.-Z. Zhang, Y.-Z. Chen, J. Xu, K.-X. Tao, G.-Y. Wang, C.-Y. Hao
Journal: Annals of Oncology (2016)
Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Beth A Christian, John G. Kuruvilla, Sonali M. Smith, Pierluigi Porcu, Kami J. Maddocks, Amy S. Ruppert, John C Byrd, Michael R. Grever, Kristie A. Blum
Journal: Blood (2015)
Normal Lymphocytes at Diagnosis and during Induction Chemotherapy in Childhood Acute Lymphoblastic Leukaemia in Peripheral Blood and Bone Marrow Are Predominantly CD3+, CD4+ or CD8+, CCR7+, CD45RA+, HLA-DR-
Authors: Kate L E Phillips, Steve E Christmas, Brian F Flanagan, Russell D Keenan
Journal: Blood (2015)
Presentation and Management of Local Anesthetic Hypersensitivty in Ukraine
Authors: Igor Kaidashev, N. Digtiar, I. Mormol, O. Demidenko, G. Granovskaya, M. Lomikivska, V. Chopyak, V. Litus, V. Babadjan, Lawrence M. DuBuske
Journal: Journal of Allergy and Clinical Immunology (2017)
Long-term Walnut Oral Immunotherapy Induces Clinically Relevant Treatment Responses in Tree Nut Allergic Children
Authors: Amy M. Scurlock, Mallik Rettiganti, Anne M. Hiegel, Erica D. Gibson, Sarah Beckwith, Suzanne E. House, James D. Sikes, Sheva K. Chervinskiy, Robbie Pesek, Tamara T. Perry, Joshua Kennedy, Peggy Chandler, Lynn Christie, Chunqiao Luo, A. Wesley Burks, Stacie M. Jones
Journal: Journal of Allergy and Clinical Immunology (2017)
NIMG-24. CLINICAL CORRELATES OF PATHOLOGY-CONFIRMED PSEUDOPROGRESSION IN GLIOBLASTOMA MULTIFORME - EXPERIENCE OVER FIVE YEARS.
Authors: Benjamin Himes, Brandon McCutcheon
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) patients are typically followed closely with serial magnetic resonance imaging (MRI) but discerning true disease progression from treatment-related changes or “pseudoprogression” is challenging. Metrics to distinguish these processes such as RANO criteria are helpful, but can often be imprecise. Here we report a series of glioblastoma patients at first imaging recurrence who underwent repeat biopsy or surgical resection, and examined their clinical course as it relates to their ultimate pathology. Surgical operative reports over five years at a single institution were reviewed for cases of surgery for first recurrence of glioblastoma. Pathology results were reviewed to determine true progression versus pseudoprogression (necrosis, gliosis, and/or inflammation without viable tumor). Patient demographics, time from completion of radiation and chemotherapy, corticosteroid use, symptoms, and suggestion of pseudoprogression in the preoperative MRI report were recorded. 83 patients were identified. Of these, 15 (18%) demonstrated pseudoprogression. Repeat resection within three or six months after completing radiation was associated with an increased rate of pseudoprogression (odds ratio 8.25 [1.24-54.72], p=0.03 and 7.49 [2.18-25.72] p=0.001, respectively). Corticosteroid treatment at presumed recurrence and the presence of clinical symptoms were not significantly associated with treatment effect versus true disease progression (odds ratios 2.63 [0.68-10.21] p=0.18, 1.45 [0.47-4.44] p=1.0, respectively). Five of 15 patients with pseudoprogression met all RANO criteria for disease progression. Seven of 15 patients met radiographic criteria but were asymptomatic. Identifying treatment-related changes versus true disease progression in patients with “recurrent” GBM presents a significant challenge. Current clinical and imaging metrics are insufficient to clearly delineate the two entities. Identifying a larger patient cohort with histologically-proven pseudoprogression may be helpful in delineating MRI correlates of this phenomenon.
Physical and mental functioning in colorectal cancer (CRC) survivors by work status.
Authors: Crystal Shereen Denlinger, Sarah Hegarty, Pamela Joyce Shapiro, Carolyn Y Fang, Andrea Marie Barsevick
Journal: Journal of Clinical Oncology (2016)

126 Background: Comorbidities and treatment-related symptoms (sx) affect overall function and may impact return to work. We evaluated SF-12 physical and mental functioning in CRC working (W) and non-working (NW) survivors. Methods: 300 Stage I-III CRC survivors age 25-70 years identified by PA Cancer Registry who completed curative therapy 3-5 years prior to study and were employed at diagnosis were surveyed with validated measures via mail-survey procedures. Current work status (working/not working), demographics, and medical factors (diagnosis, treatment, comorbidities) were assessed, as was fatigue, insomnia, distress, cognitive sx, neuropathy, bowel sx, and urinary sx. Study approved by PA Department of Health; participants (pts) provided informed consent. Results: Pts average age 57 yrs (80% &lt; 65 yrs), 56% male, 87% white, 67% educated beyond high school, 73% married. 56% had rectal cancer, 51% had chemotherapy, 39% had radiation therapy, 16% had an ostomy. Work status at survey: 226 pts (75%) W; 74 pts (25%) NW. Higher comorbidity number was associated with lower physical (PCS) component scores in both W and NW groups (p = 0.004 and 0.013), and with lower mental (MCS) component scores in the NW group (p = 0.004). Among W pts, predictors of lower PCS were fatigue (p = 0.001), bowel problems (p &lt; 0.001), neuropathy (p = 0.009), and being male (p = 0.03). Predictors of lower MCS were fatigue (p = 0.003), cognitive issues (p &lt; 0.001), and distress (p &lt; 0.001). Among NW pts, predictors of lower PCS were fatigue (p = 0.02), neuropathy (p = 0.007), ostomy presence (p = 0.015), and being unmarried (p = 0.007). Predictors of lower MCS were distress (p &lt; 0.001) and younger age (p = 0.007). Conclusions: Both W and NW CRC survivors have significant comorbidity and sx burden associated with poorer physical and mental functioning. Fatigue, neuropathy, and distress were predictors in both groups, while cognitive and bowel sx predicted poorer function among W survivors. Intervening on these modifiable sx may increase survivors’ return to work and improve functioning for those who do. Next steps will focus on intensive management of modifiable sx to determine the effect on physical and mental functioning and potential for returning to work after treatment.
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials
Authors: M. Davies, J.J. Grob, G.V. Long, K. Flaherty, P. Nathan, A. Ribas, D. Schadendorf, B. Mookerjee, J.J. Legos, S. Lane, C. Robert
Journal: Annals of Oncology (2016)
Oral Beclomethasone Dipropionate Monotherapy as An Initial Treatment for Stage 1-2 Gastrointestinal Tract Acute Graft-Versus-Host Disease Following Unrelated Cord Blood Transplantation.
Authors: Hisashi Yamamoto, Yumiko Uchida, Tadaaki Ito, Naoyuki Uchida, Kazuya Ishiwata, Nobuaki Nakano, Shinsuke Takagi, Masanori Tsuji, Hideki Araoka, Yuki Mori-Asano, Naofumi Matsuno, Kazuhiro Masuoka, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Masahiro Hayashi, Shuichi Taniguchi
Journal: Blood (2009)
Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432
Authors: Karthik Venkatakrishnan, Ramesh K Ramanathan, John Sarantopoulos, Daniel L Mulkerin, Stephen I Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A Rudek, Percy Ivy, Chris H Takimoto, Rachel Neuwirth, Sudha Parasuraman, Patricia M LoRusso
Journal: Blood (2010)
Cardiac nuclear receptors: architects of mitochondrial structure and function
Authors: Rick B. Vega, Daniel P. Kelly
Journal: Journal of Clinical Investigation (2017)

The adult heart is uniquely designed and equipped to provide a continuous supply of energy in the form of ATP to support persistent contractile function. This high-capacity energy transduction system is the result of a remarkable surge in mitochondrial biogenesis and maturation during the fetal-to-adult transition in cardiac development. Substantial evidence indicates that nuclear receptor signaling is integral to dynamic changes in the cardiac mitochondrial phenotype in response to developmental cues, in response to diverse postnatal physiologic conditions, and in disease states such as heart failure. A subset of cardiac-enriched nuclear receptors serve to match mitochondrial fuel preferences and capacity for ATP production with changing energy demands of the heart. In this Review, we describe the role of specific nuclear receptors and their coregulators in the dynamic control of mitochondrial biogenesis and energy metabolism in the normal and diseased heart.
CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming
Authors: Anna Brewitz, Sarah Eickhoff, Sabrina Dähling, Thomas Quast, Sammy Bedoui, Richard A. Kroczek, Christian Kurts, Natalio Garbi, Winfried Barchet, Matteo Iannacone, Frederick Klauschen, Waldemar Kolanus, Tsuneyasu Kaisho, Marco Colonna, Ronald N. Germain, Wolfgang Kastenmüller
Journal: Immunity (2017)
Persistence of immune responses induced by Ebola virus vaccines
Authors: Matthew D Snape
Journal: The Lancet Global Health (2017)

The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% effectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modified to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of effectiveness from 10 days post-immunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole-population intervention).
Measuring Circulating Complement Activation Products in MPO and PR3 ANCA Vasculitis
Authors: Eveline Y. Wu, Sonia Boyer, Elizabeth McInnis, Yichun Hu, Susan Hogan, Caroline Poulton, Peiqi Hu, Hong Xiao, Ronald Falk, Charles Jennette, Donna Bunch, Patrick Nachman
Journal: Journal of Allergy and Clinical Immunology (2017)
Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria
Authors: Jennifer L. Trevor, Eric S. Bradford, Frank C. Albers, Daniel J. Bratton, Jie Wang-Jairaj, Linda M. Nelsen, Geoffrey L. Chupp, Antoine Magnan, Anneke ten Brinke
Journal: Journal of Allergy and Clinical Immunology (2017)
12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML
Authors: Alex George Kanellopoulos, Shankaranarayana Paneesha, Evgenia Xenou, Iman Qureshi, Dewi Tomos Eden, David John Sutton, Rebecca Pryor, Lorna Cain, Carolina Arbuthnot, Richard Lovell, Anton Borg, Katie Randall, Kathy Holder, Julie Suhr, Lynda Baker, Lynn Ryan, Maria Kaparou, Bhuvan Kishore, Emmanouil Nikolousis
Journal: Blood (2016)
Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.
Authors: Mark Kirschbaum, Maria Delioukina, Leslie Popplewell, David S. Snyder, Pablo Parker, Robert Chen, Jasmine Zain, Deron Matsuoka, Nony Obadike, Paul Frankel, Auayporn P. Nademanee, Stephen J Forman
Journal: Blood (2009)